These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 21880985

  • 1. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.
    Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, Ravetch JV, Lycke NY.
    J Immunol; 2011 Oct 01; 187(7):3641-52. PubMed ID: 21880985
    [Abstract] [Full Text] [Related]

  • 2. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 01; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 3. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L, Sverremark E, Ekman L, Schön K, Löwenadler B, Fernandez C, Lycke N.
    J Immunol; 2000 Jun 15; 164(12):6276-86. PubMed ID: 10843681
    [Abstract] [Full Text] [Related]

  • 4. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 5. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 6. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 15; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 7. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA, Stensson A, Schön K, Lycke N.
    Scand J Immunol; 2006 Feb 15; 63(2):97-105. PubMed ID: 16476008
    [Abstract] [Full Text] [Related]

  • 8. The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization.
    Schussek S, Bernasconi V, Mattsson J, Wenzel UA, Strömberg A, Gribonika I, Schön K, Lycke NY.
    Mucosal Immunol; 2020 May 15; 13(3):545-557. PubMed ID: 31959882
    [Abstract] [Full Text] [Related]

  • 9. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
    Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG.
    J Immunol; 1998 Nov 01; 161(9):4549-54. PubMed ID: 9794381
    [Abstract] [Full Text] [Related]

  • 10. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 11. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N, Schön K.
    Vaccine; 2001 Mar 21; 19(17-19):2542-8. PubMed ID: 11257390
    [Abstract] [Full Text] [Related]

  • 12. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.
    Vaccine; 2006 Jan 30; 24(5):544-51. PubMed ID: 16169634
    [Abstract] [Full Text] [Related]

  • 13. Antibody-independent B cell-intrinsic and -extrinsic roles for CD21/35.
    Rossbacher J, Haberman AM, Neschen S, Khalil A, Shlomchik MJ.
    Eur J Immunol; 2006 Sep 30; 36(9):2384-93. PubMed ID: 16906534
    [Abstract] [Full Text] [Related]

  • 14. A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.
    Bemark M, Bergqvist P, Stensson A, Holmberg A, Mattsson J, Lycke NY.
    J Immunol; 2011 Feb 01; 186(3):1399-410. PubMed ID: 21199899
    [Abstract] [Full Text] [Related]

  • 15. Marginal zone B cells transport and deposit IgM-containing immune complexes onto follicular dendritic cells.
    Ferguson AR, Youd ME, Corley RB.
    Int Immunol; 2004 Oct 01; 16(10):1411-22. PubMed ID: 15326094
    [Abstract] [Full Text] [Related]

  • 16. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.
    Vaccine; 2011 May 23; 29(23):3951-61. PubMed ID: 21481325
    [Abstract] [Full Text] [Related]

  • 17. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.
    Infect Immun; 2007 Jan 23; 75(1):408-16. PubMed ID: 17074845
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M, Ohta R, Varela JC, Song H, Tomlinson S.
    Cancer Res; 2007 Oct 01; 67(19):9535-41. PubMed ID: 17909064
    [Abstract] [Full Text] [Related]

  • 19. AID-expressing germinal center B cells cluster normally within lymph node follicles in the absence of FDC-M1+ CD35+ follicular dendritic cells but dissipate prematurely.
    Boulianne B, Le MX, Ward LA, Meng L, Haddad D, Li C, Martin A, Gommerman JL.
    J Immunol; 2013 Nov 01; 191(9):4521-30. PubMed ID: 24068672
    [Abstract] [Full Text] [Related]

  • 20. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
    Eriksson AM, Schön KM, Lycke NY.
    J Immunol; 2004 Sep 01; 173(5):3310-9. PubMed ID: 15322194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.